TL;DR
Findings suggest ketamine reduces acute relapse vulnerability to opioids through coordinated modulation of opioid and glutamatergic systems, highlighting its potential as a novel intervention for OUD.
Opioid use disorder (OUD) remains a chronic, relapsing condition; in the United States in 2024, approximately 79,000 drug-overdose deaths occurred, including about 54,000 involving opioids (NCHS Data Brief, 2026 (Centers for Disease Control and Prevention, National Center for Health Statistics, 2026)). Although current...
Introduction Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurob...
It is indicated that stereochemical and subunit-selective modulation of GABAA receptors critically determines circuit-level outcomes following stress and reinforce α5-GABAA receptors as a key target for normalizing hippocampal-driven dopamine system dysfunction associated with psychosis-relevant states.
It is suggested that CP-AMPAR recruitment in the NAc, a mechanism classically linked to the incubation of cocaine craving, may also contribute to abstinence-dependent increases in drug motivation that emerge earlier in females.
Preclinical experiments have revealed much about opioid withdrawal, but have failed to discover novel treatments. The preclinical literature is dominated by experiments examining naloxone-precipitated withdrawal from morphine in male rats. These studies report a number of putative treatments for opioid withdrawal, none...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
